NAPOLEON-2: Nanoliposomal Irinotecan and Neutropenia in Patients With Pancreatic Cancer

At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Tsuyoshi Shirakawa, MD, PhD, of the Oncology Treatment Study Group, highlighted the results of the NAPOLEON-2 trial, including how the real-world data from the study compare to clinical trial findings in terms of the frequency and severity of neutropenia observed with nanoliposomal irinotecan and fluorouracil with folinic acid.